Marietta S. Truger

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

MDS without clonal marker: when depth outperforms breadth.

MDS without clonal marker: when depth outperforms breadth.

Journal: Leukemia
Published: March 11, 2026

Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosis.

Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosis.

Journal: Leukemia
Published: February 06, 2026

Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.

Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.

Journal: Leukemia
Published: January 31, 2026

Clonal independence of CHIP-associated mutations in multiple myeloma.

Clonal independence of CHIP-associated mutations in multiple myeloma.

Journal: Leukemia & lymphoma
Published: January 28, 2026

Myeloid Neoplasms With a t(5;12)(q31;p13) and an Associated ETV6::ACSL6 Gene Fusion Are Diagnostically Challenging and Have a Poor Prognosis.

Myeloid Neoplasms With a t(5;12)(q31;p13) and an Associated ETV6::ACSL6 Gene Fusion Are Diagnostically Challenging and Have a Poor Prognosis.

Journal: Genes, chromosomes & cancer
Published: January 21, 2026

Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin.

Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin.

Journal: Leukemia
Published: December 11, 2025

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

Journal: Leukemia
Published: December 06, 2025

Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.

Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.

Journal: Leukemia
Published: September 29, 2025

Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.

Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.

Journal: Haematologica
Published: September 23, 2025

Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.

Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.

Journal: Haematologica
Published: September 11, 2025

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Journal: Leukemia
Published: August 15, 2025

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Journal: Clinical epigenetics
Published: July 03, 2025
Showing 1-12 of 30

Last Updated: 09/26/2026